The EHR May Be Becoming the Database: Who Owns the Interface Above It?
Dr. Dereck Mush, MD, MBA
Causaly
Accelerates scientific research discovery through artificial intelligence driven literature synthesis.
What they do
Causaly provides an artificial intelligence platform that reads, understands, and visualizes millions of biomedical documents. Pharmaceutical researchers and clinical trial teams use the platform to find biological connections, map disease pathways, and identify drug targets.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Literature search and synthesis
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- London, United Kingdom
- Region
- Europe
- Founded
- 2017
- Total funding
- $93M raised
Notable investors: Index Ventures, Marathon Venture Capital, Pentech, EBRD.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Beyond the Scribe: How Ambient AI Is Morphing into Point-of-Care Clinical Reasoning and EHR Operating Systems
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA